256 related articles for article (PubMed ID: 23503643)
1. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
[TBL] [Abstract][Full Text] [Related]
2. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
[TBL] [Abstract][Full Text] [Related]
3. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
4. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
6. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
Robertson SJ; Ibrahim MFK; Stober C; Hilton J; Kos Z; Mazzarello S; Ramsay T; Fergusson D; Vandermeer L; Mallick R; Arnaout A; Dent SF; Segal R; Sehdev S; Gertler S; Hutton B; Clemons M
J Eval Clin Pract; 2019 Apr; 25(2):196-204. PubMed ID: 30672056
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
Hou Y; Zynger DL; Li X; Li Z
Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
[TBL] [Abstract][Full Text] [Related]
8. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
[TBL] [Abstract][Full Text] [Related]
10. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
11. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
[TBL] [Abstract][Full Text] [Related]
12. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Farrugia DJ; Landmann A; Zhu L; Diego EJ; Johnson RR; Bonaventura M; Soran A; Dabbs DJ; Clark BZ; Puhalla SL; Jankowitz RC; Brufsky AM; Lembersky BC; Ahrendt GM; McAuliffe PF; Bhargava R
Mod Pathol; 2017 Aug; 30(8):1078-1085. PubMed ID: 28548119
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
Walts AE; Mirocha JM; Bose S
Breast J; 2018 Nov; 24(6):951-956. PubMed ID: 30230113
[TBL] [Abstract][Full Text] [Related]
14. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
Robertson SJ; Pond GR; Hilton J; Petkiewicz SL; Ayroud Y; Kos Z; Gravel DH; Stober C; Vandermeer L; Arnaout A; Clemons M
Clin Breast Cancer; 2020 Feb; 20(1):61-67. PubMed ID: 31551182
[TBL] [Abstract][Full Text] [Related]
15. Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.
Li H; Wang J; Li Z; Dababneh M; Wang F; Zhao P; Smith GH; Teodoro G; Li M; Kong J; Li X
Front Med (Lausanne); 2022; 9():886763. PubMed ID: 35775006
[TBL] [Abstract][Full Text] [Related]
16. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
[TBL] [Abstract][Full Text] [Related]
17. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
[TBL] [Abstract][Full Text] [Related]
18. The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Bhargava R; Clark BZ; Carter GJ; Brufsky AM; Dabbs DJ
Mod Pathol; 2020 Aug; 33(8):1563-1570. PubMed ID: 32203092
[TBL] [Abstract][Full Text] [Related]
19. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
20. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
